标题：胸腺肽α1联合康艾注射液对肝细胞癌患者TACE术后细胞免疫功能的影响

      作者：刘凌云，孟 洁，何 沙，吕 一，卢永刚
    (柳州市柳铁中心医院肝胆胰外科，广西 柳州 545007)

      卷次： 2013年24卷24期

      【摘要】 目的 观察联合使用胸腺肽α1和康艾注射液对肝细胞癌患者经肝动脉化疗栓塞术(TACE)术后细
胞免疫功能的影响。方法 随机选取我科住院的肝细胞癌行TACE治疗患者51例，分为A、B两组，A组26例术
后第1天开始联合使用胸腺肽α1及康艾注射液进行一个疗程治疗，B组25例除不使用胸腺肽α1外，其他治疗同A
组，C组42例为健康体检者。分别在TACE术后第一天胸腺肽α1及康艾注射液治疗前、治疗后1个月应用流式细
胞术检测其外周血T淋巴细胞亚群及NK细胞水平。结果 肝细胞癌患者细胞免疫功能较正常人显著降低，A
组治疗后外周血CD3+、CD4+、CD4+/CD8+比值及NK细胞均明显高于治疗前(P<0.05)，而CD8+水平明显低于治疗前
(P<0.05)，B组治疗前后T淋巴细胞亚群及NK细胞无明显变化(P>0.05)。结论 联合使用胸腺肽α1与康艾注射液
可提高肝细胞癌患者TACE术后细胞免疫功能。

      【关键词】 胸腺肽α1；康艾注射液；肝细胞癌；免疫功能；经肝动脉化疗栓塞术

      【中图分类号】 R735.7 【文献标识码】 A 【文章编号】 1003—6350（2013）24—3605—03


Effect of thymosin α 1 combined with Kangai injection on cellular immune function of patients with
hepatocellular carcinoma after TACE.
LIU Ling-yun, MENG Jie, HE Sha, LV Yi, LU Yong-gang. Department of
Hepatobiliary and Pancreatic Surgery, Liuzhou Municipal Liutie Central Hospital, Liuzhou 545007, Guangxi, CHINA

【Abstract】 Objective To investigate the effect of thymosin α1 combined with Kangai injection on cellular
immune function of patients with hepatocellular carcinoma after TACE. Methods Fifty-one patients with hepatocel-
lular carcinoma treated by TACE were randomly divided into group A and group B. Patients in group A (n=26) were
treated by thymosin α 1 combined with Kangai injection from the first day after TACE for one course of treatment,
while those in group B (n=25) were only treated by Kangai injection for one course of treatment. Forty-two healthy in-
dividuals were selected as group C. Peripheral blood T lymphocyte subsets and NK cells were detected by flow cytom-
etry in the first day (before thymosin α1 and Kangai injection) and one month after TACE treatment. Results The cel-
lular immune function in patients with hepatocellular carcinoma were significantly lower than that in the healthy peo-
ple. CD3+, CD4+, CD4+/CD8+ ratio and NK cells were significantly higher than those before thymosin α1 and Kangai in-
jection treatment in group A (all P<0.05), while CD8+ was significantly lower than that before thymosin α1 and Kangai
injection treatment (P<0.05). There was no statistically significant difference in T lymphocyte subsets and NK cells in
group B before and after treatment (all P>0.05). Conclusion The combined use of thymosin α1 and Kangai injection
after TACE can improve cellular immune function of patients with hepatocellular carcinoma.